What Is the Difference Between CPT Code 77063 and 77067?

CPT code 77067 covers a standard two-dimensional (2D) screening mammogram, while CPT code 77063 covers screening digital breast tomosynthesis, commonly called 3D mammography. The critical distinction is that 77063 is an add-on code, meaning it cannot be billed on its own and must be paired with a primary mammography code like 77067. In practical terms, 77067 is the flat X-ray image most people picture when they think of a mammogram, and 77063 represents the additional 3D layer that some facilities now include in the screening process.

What Each Code Represents

CPT 77067 describes a bilateral screening mammogram using two views of each breast. This is the standard screening exam recommended for routine breast cancer detection. The machine compresses the breast and takes images from two angles, producing flat 2D pictures that a radiologist reads for signs of abnormalities. When a facility bills 77067, it is billing for this conventional digital mammography exam.

CPT 77063, by contrast, describes bilateral screening digital breast tomosynthesis. During this procedure, the X-ray arm sweeps in a small arc around the compressed breast, capturing a series of low-dose images from multiple angles. Software then reconstructs those images into thin slices, allowing the radiologist to scroll through the breast tissue layer by layer rather than viewing it as a single flattened image. The code is defined as an add-on to the primary screening procedure, so it appears on a claim alongside 77067 (or its Medicare equivalent) rather than standing alone.

How the Two Codes Work Together on a Bill

Because 77063 is designated as a supplemental code, a patient who receives both 2D and 3D imaging during a single screening visit will see both codes on her bill or explanation of benefits. The facility bills 77067 for the standard mammogram and adds 77063 for the tomosynthesis component. Medicare’s administrative contractor guidance explicitly lists 77063 as an add-on to be used alongside the primary screening mammography code when tomosynthesis is performed in addition to 2D imaging.

This add-on structure matters for billing offices because submitting 77063 without the accompanying primary code will typically result in a claim denial. It also matters for patients because the two codes may carry different cost-sharing rules. A standard screening mammogram billed under 77067 is generally covered as a preventive service with no out-of-pocket cost under most insurance plans. The 3D add-on billed under 77063 may or may not be covered at the same zero-cost level depending on the payer and the state, which can lead to a surprise balance for patients who assumed the entire screening was fully covered.

Why Tomosynthesis Was Given Its Own Code

When digital breast tomosynthesis entered clinical use, it was a genuinely different imaging technique layered on top of existing mammography rather than a replacement for it. Early protocols had radiologists acquire a conventional 2D mammogram and then perform the 3D sweep as an additional step. Creating a separate add-on code made sense because the technology required extra machine time, extra radiation exposure, and extra radiologist interpretation. The separate code also gave payers a mechanism to decide independently whether to cover the 3D component.

Over time, some manufacturers developed “synthetic 2D” images reconstructed from the 3D tomosynthesis data, which can eliminate the need for a separate conventional 2D acquisition. In facilities using synthetic 2D, the patient undergoes only the 3D sweep, and the software generates the 2D-equivalent views from that data. This changes the clinical workflow and the radiation profile but does not always change the billing. Facilities using synthetic 2D may still bill both codes depending on payer rules, which is one reason the coding landscape can feel confusing.

Clinical Differences Between the Two Procedures

From the patient’s perspective, the experience of a 2D mammogram versus a combined 2D-plus-3D exam is nearly identical. The breast is compressed in the same way, the positioning is the same, and the exam takes only a few extra seconds for the tomosynthesis sweep. The meaningful differences are in what the radiologist sees on the screen afterward.

A standard 2D mammogram compresses all the breast tissue into a single flat image. Overlapping tissue can hide small cancers or create shadows that look suspicious but turn out to be nothing. Tomosynthesis reduces this overlap problem by letting the radiologist examine the tissue one thin slice at a time. Think of it as the difference between looking at a closed book from the outside versus flipping through it page by page.

A large comparative study of women aged 40 to 64 found that tomosynthesis detected about 4.9 cancers per 1,000 screens compared with 3.8 per 1,000 screens for standard 2D mammography, a meaningful increase in detection.² A European population-based screening program reported an even larger jump, finding over 50% more cancers with tomosynthesis than with 2D mammography alone.³

Recall Rates and False Alarms

Getting called back after a screening mammogram is stressful, and one of the selling points of tomosynthesis has been its potential to reduce these false alarms. The layer-by-layer view helps radiologists confirm that a suspicious shadow is just overlapping normal tissue, which means fewer unnecessary callbacks.

The data on this is real but the benefit is modest for the overall population. In the large study of women 40 to 64, tomosynthesis was associated with slightly fewer recalls than 2D mammography across the full group. The benefit was more pronounced in younger women aged 40 to 44, who tend to have denser breast tissue: recall dropped from about 164 per 1,000 screens with 2D to about 153 per 1,000 with tomosynthesis.² In the European program, the recall rate dropped by nearly 19% with tomosynthesis.³

There is a trade-off worth noting, though. Tomosynthesis also led to higher biopsy rates in the U.S. study, roughly 19.6 biopsies per 1,000 screens versus 15.2 for 2D alone.² More cancers were being found, but so were more borderline findings that prompted tissue sampling. Whether that represents beneficial early detection or a degree of overdiagnosis is an ongoing discussion in the field.

Dense Breast Tissue and Where the 3D Advantage Grows

Breast density has a major influence on how useful the 3D add-on (77063) turns out to be. Dense breast tissue appears white on a mammogram, and so do many cancers. On a flat 2D image, a small tumor nestled in dense tissue can be nearly invisible. This is where tomosynthesis earns its keep most convincingly.

A meta-analysis of prospective trials comparing 2D and 3D mammography in the same women found that tomosynthesis detected roughly 3.9 additional cancers per 1,000 screens in women with dense breasts.⁴ That is a substantial incremental gain, and it has driven many states to pass dense-breast notification laws that inform women of their breast density and sometimes mandate insurance coverage of supplemental screening.

A European screening trial broke the results down by density levels and found that the sensitivity advantage of tomosynthesis was largest in the densest breasts. In the highest density group, tomosynthesis caught about 81% of cancers compared with just 43% for standard 2D mammography. That is nearly double the detection rate in exactly the population where missed cancers matter most.⁵ In less dense breasts, both technologies performed more similarly, which makes sense because there is less overlapping tissue to obscure findings.

For women who know they have heterogeneously or extremely dense breasts, seeing code 77063 on their bill often reflects a clinically meaningful upgrade in their screening. For women with fatty or scattered-density breasts, the improvement exists but is less dramatic.

Radiation Dose Differences

Because tomosynthesis involves an additional series of X-ray exposures beyond the standard 2D images, the combined exam delivers more radiation than 2D mammography alone. This is worth understanding even though the absolute doses involved are low.

A review of dose studies found that when a single-view tomosynthesis acquisition was combined with a full 2D mammogram, the total dose ranged from about 1.0 to 1.5 times that of 2D alone. When two-view tomosynthesis was added to a full 2D exam, the dose roughly doubled, reaching 2.0 to 2.2 times the 2D dose.⁶ That same review found that using synthetic 2D images instead of acquiring a separate conventional 2D mammogram cut the combined dose by about 45%, which is one reason the shift toward synthetic 2D has been welcome from a safety standpoint.

A direct comparison measuring dose to various organs found that a tomosynthesis screening session increased the effective dose by about 22% compared with a standard 2D mammogram. In absolute numbers, the effective dose was about 0.44 millisieverts for the 3D exam versus 0.34 millisieverts for 2D.⁷ To put that in perspective, the annual background radiation exposure from natural sources averages roughly 3 millisieverts, so the additional dose from a yearly tomosynthesis screening is a small fraction of what you absorb just by existing. The radiation concern is real in the aggregate sense that any unnecessary exposure should be avoided, but for most women, the cancer-detection benefit of 3D screening outweighs the marginal dose increase.

Insurance Coverage and Out-of-Pocket Costs

This is where the two codes create the most confusion for patients. Under the Affordable Care Act, preventive screening mammography is required to be covered with no cost sharing for women at recommended ages. Code 77067, the standard 2D screening mammogram, clearly falls under this mandate. Code 77063, the tomosynthesis add-on, has been handled less uniformly.

Many states have passed laws requiring insurers to cover 3D mammography at the same zero-cost-sharing level as 2D mammography. In those states, both codes are covered and you pay nothing for either. In states without such mandates, some insurers voluntarily cover 77063 while others treat it as an optional upgrade and pass along a portion of the cost, which can range from $50 to several hundred dollars depending on the facility and the plan.

Medicare has its own path. Traditional Medicare covers screening mammography and has specific billing guidance for tomosynthesis using code 77063 as an add-on.¹ Coverage of the 3D component under Medicare has evolved, and beneficiaries should confirm current coverage rules with their plan or the facility before the exam. Medicare Advantage plans may have different terms than Original Medicare.

The upshot is that seeing 77063 on a bill does not automatically mean you owe money, but it does mean there is a separate line item that your insurer may or may not cover at 100%. Calling your insurer or the imaging center before the appointment is the most reliable way to avoid a surprise bill for the 3D portion.

When Only One Code Appears on Your Bill

If your bill shows 77067 but not 77063, you received a standard 2D screening mammogram without the 3D component. This is still a perfectly valid screening exam and is what population-level screening guidelines have been built on for decades. Not every facility has tomosynthesis equipment, and not every screening protocol includes it.

If your bill shows 77063 but not 77067 (or a corresponding primary code), something may be miscoded. Since 77063 is an add-on, it should not appear without its parent code. In rare cases, a facility using a combo protocol that generates synthetic 2D from the tomosynthesis data might code the encounter differently, but the standard expectation is that both codes appear together. If the billing looks odd, it is worth calling the facility’s billing department to clarify.

There are also separate CPT codes for diagnostic mammography (as opposed to screening), which apply when you have symptoms, a prior abnormal finding, or a clinical concern. Diagnostic codes carry different numbers and different coverage rules, so the 77067/77063 pair specifically refers to routine screening in patients with no known breast problems at the time of the exam.

Screening Versus Diagnostic Codes and Common Mix-Ups

A frequent source of billing frustration arises when a screening mammogram gets reclassified as diagnostic during the visit. If the radiologist spots something unusual on your screening images and performs additional views or an ultrasound right then and there, the facility may bill part of the encounter under diagnostic codes rather than screening codes. This can change your cost sharing because diagnostic imaging is not always subject to the same zero-cost preventive mandate.

In this situation, the 77067 for the initial screening portion should still be billed as preventive. But any additional workup is a separate charge under diagnostic codes. Patients sometimes see the combined bill and assume the screening itself was not covered, when really the extra charges are for the follow-up imaging that happened in the same session. Asking the billing office to separate the screening and diagnostic components can sometimes resolve the confusion.

It is also worth knowing that if you go in for a screening mammogram and tell the technologist about a new lump or breast symptom, the facility may code the entire visit as diagnostic from the start. If you want the screening portion covered as preventive, scheduling a separate visit for the symptom evaluation is sometimes the cleaner approach, though practices vary by facility and insurer.

The Shift Toward Synthetic 2D and Future Coding

The clinical trend is moving toward using synthetic 2D images generated from the tomosynthesis data, eliminating the need for a separate conventional 2D acquisition. This approach delivers the diagnostic information of both 2D and 3D imaging from a single breast compression, which is more comfortable for the patient and reduces radiation exposure. The dose review noted that substituting synthetic 2D for conventional 2D reduced the combined dose by about 45%.⁶

As synthetic 2D becomes more widespread, the two-code billing structure of 77067 plus 77063 may eventually feel outdated. Some in the radiology community have argued that tomosynthesis should have its own standalone screening code rather than being perpetually treated as an add-on to a technology it is gradually replacing. For now, the coding framework has not caught up with the clinical reality at many facilities, which means patients and billers still navigate the paired-code system even when the underlying imaging workflow has simplified. Whether future CPT updates collapse these into a single code remains an open question, but the current billing architecture reflects the era when 3D mammography was introduced as a supplement to, not a substitute for, the conventional 2D exam.